KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Leases: 2019-2025

Historic Current Leases for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to $2.4 million.

  • Esperion Therapeutics' Current Leases fell 13.02% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 13.02%. This contributed to the annual value of $2.7 million for FY2024, which is 76.50% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Current Leases of $2.4 million as of Q3 2025, which was down 12.93% from $2.7 million recorded in Q2 2025.
  • Esperion Therapeutics' Current Leases' 5-year high stood at $2.8 million during Q1 2025, with a 5-year trough of $305,000 in Q1 2023.
  • In the last 3 years, Esperion Therapeutics' Current Leases had a median value of $2.5 million in 2024 and averaged $2.0 million.
  • In the last 5 years, Esperion Therapeutics' Current Leases crashed by 74.94% in 2023 and then skyrocketed by 732.46% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Current Leases (Quarterly) stood at $1.4 million in 2021, then tumbled by 72.41% to $384,000 in 2022, then soared by 304.43% to $1.6 million in 2023, then surged by 76.50% to $2.7 million in 2024, then fell by 13.02% to $2.4 million in 2025.
  • Its Current Leases stands at $2.4 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.8 million for Q1 2025.